To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Starpharma Signs Cancer Drug Agreement with AstraZeneca
Starpharma Holdings Ltd today announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.
The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.
The identity of the anti-cancer molecules to be studied is covered by confidentiality restrictions, but Starpharma notes that the arrangement does not relate to docetaxel or to dendrimer conjugates of docetaxel. Further details of the arrangement between the parties were not disclosed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
